Navigation Links
Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
Date:1/30/2013

of the immune system that ensure generation of a robust and specific immune response. What makes this modification unique is that it amplifies the vaccine potency of the HER2 fragment without loosing specificity, unlike many non-specific immune stimulants. The Ii-Key modification can be added to many different 'payloads' to generate a specific and robust immune response. Given the increasing interest in cancer immunotherapy, this will be very attractive to companies wishing to 'supercharge' their specific vaccines.

The positive interim data of the AE37 trial have received particular attention given the robust and well-designed nature of the Phase IIb trial. In addition to being the only randomized, controlled and blinded study conducted with this type of HER2 targeted immunotherapy, it is also the largest vaccine therapy study conducted in the adjuvant breast cancer setting to date (330 patients). In recognition of the quality of the trial and encouraging results, the abstract reporting the interim results was recognized with a 2012 American Society of Clinical Oncology (ASCO) Merit Award bestowed by the Conquer Cancer Foundation and the 2012 Scientific Program Committee of ASCO. Further, the FDA has given the company the green light to proceed with submission of a Special Protocol Assessment for the Phase III trial.

Antigen Express is well positioned to execute on its business model, which includes potential out-licensing of additional clinical development of its lead compound in early breast cancer while pursuing additional products using its proprietary immunotherapy Ii-Key technology platform upon which AE37 is based. The advancement of AE37 in breast cancer clinical development will help to validate the company's immune technology platform. Low expression of the HER2 target is widespread among a variety of cancers including breast, prostate, ovarian, lung and cancers of the GI tract suggesting potential future areas for clinical research. Addit
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
10. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
11. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... ARBOR, Mich., May 14, 2012  Synthetic Biologics, Inc. (NYSE ... DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, ... Senior Vice President of Clinical & Regulatory Affairs. In ... design and implementation of all aspects of clinical development, ...
... 11, 2012 Dynatronics Corporation (NASDAQ: DYNT ) ... months ended March 31, 2012 during the morning of Tuesday, ... conference call for investors later that day at 3:30 p.m. ... month periods.  Those interested in participating should call (800) 676-3536. ...
Cached Medicine Technology:Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 2Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 3
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... teens, TOPEKA, Kan., Oct. 19 Attorney General ... with new 30-second,radio public service announcements set to air ... coincide with the busy fall season and will,air more ... November. "With teens heading off to parties, dances ...
... recent study by Celent, a leading,financial services technology research ... of eight firms leading the way as a change ... transactions. Celent,s Healthcare Banking research service based its ... Mellon,s Treasury Services division to,apply its scale, technology and ...
... SPRINGS, Colo., Oct. 19 ,Spectranetics Corporation (Nasdaq: ... 2007 third quarter financial results prior to market ... host an,investment-community conference call beginning at 9:00 a.m. ... 31 to discuss those results,and to answer questions. ...
... SANTA ANA, Calif., Oct. 19 Today, Integrated,Healthcare ... owner of,four Orange County hospitals, announced that effective ... of all of its debt instruments. The,Company said ... with Medical,Capital Corporation and affiliates of Anaheim, California, ...
... Company,(Nasdaq: PRGO ; TASE) today announced that it ... on Thursday, November 1, 2007 at,approximately 8:00 a.m. (ET). ... (ET) hosted by Joseph C. Papa, Perrigo,s President and ... live via webcast to interested,parties on the Perrigo website ...
... AAFP President Michael Fleming, MD will serve as Digital,s Medical ... Director ... Healthcare, a Wake,Forest, NC company specializing in retinal risk assessment for ... for Primary Care. In his new role, Dr. Fleming will,provide Digital ...
Cached Medicine News:Health News:Morrison Takes Aim at Underage Drinking in New Radio Campaign 2Health News:The Bank of New York Mellon Recognized as Change Agent Shaping the Direction of Healthcare Transaction Processing 2Health News:Spectranetics to Hold 2007 Third Quarter Financial Results Conference Call on October 31 2Health News:IHHI Announces Completion of Re-Financing 2Health News:Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director 2
... drape sheets with a low-profile, roomy ... the operative site during arthroscopic surgery. ... ports for drainage. , ,The ... a standard pack, or in custom ...
... includes bed side and near patient testing ... This growth has posed unique problems for ... and quality responsibility to decentralized areas focused ... Compounding the problem is the reality of ...
... First Consolidated Workstation to Automate Deparaffinization, ... Staining,Now you can perform deparaffinization, pretreatment, ... routine slide washing with a single ... preprogrammed Vysis protocols for fluorescence in ...
... sample preparation platform is an efficient system ... from patient samples using novel magnetic particle ... sample preparation and is cabable of processing ... a 1 ml sample volume., ,This platform ...
Medicine Products: